OBIO

Company Overview — What Does Orchestra BioMed Holdings, Inc. Do?

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York. Orchestra BioMed Holdings, Inc. (OBIO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Roderick T. Wong and employs approximately 4 people. With a market capitalization of $254M, OBIO is one of the notable companies in the Healthcare sector.

Orchestra BioMed Holdings, Inc. (OBIO) Stock Rating — Reduce (April 2026)

As of April 2026, Orchestra BioMed Holdings, Inc. receives a Reduce rating with a composite score of 30.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.OBIO ranks #2,528 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Orchestra BioMed Holdings, Inc. ranks #324 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

OBIO Stock Price and 52-Week Range

Orchestra BioMed Holdings, Inc. (OBIO) currently trades at $4.13. The stock lost $0.10 (2.4%) in the most recent trading session. The 52-week high for OBIO is $5.42, which means the stock is currently trading -23.9% from its annual peak. The 52-week low is $2.20, putting the stock 87.7% above its annual trough. Recent trading volume was 106K shares, suggesting relatively thin trading activity.

Is OBIO Overvalued or Undervalued? — Valuation Analysis

Orchestra BioMed Holdings, Inc. (OBIO) carries a value factor score of 19/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.65x, versus the sector average of 2.75x. The price-to-sales ratio is 70.19x, compared to 1.66x for the average Healthcare stock.

At current multiples, Orchestra BioMed Holdings, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Orchestra BioMed Holdings, Inc. Profitability — ROE, Margins, and Quality Score

Orchestra BioMed Holdings, Inc. (OBIO) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -138.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -64.8% versus the sector average of -33.1%.

On a margin basis, Orchestra BioMed Holdings, Inc. reports gross margins of 94.2%, compared to 71.5% for the sector. The operating margin is -2126.7% (sector: -66.1%). Net profit margin stands at -2114.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 10.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

OBIO Debt, Balance Sheet, and Financial Health

Orchestra BioMed Holdings, Inc. has a debt-to-equity ratio of 28.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.45x, indicating strong short-term liquidity. Total debt on the balance sheet is $15M. Cash and equivalents stand at $42M.

OBIO has a beta of 1.52, meaning it is more volatile than the broader market — a $10,000 investment in OBIO would be expected to move 51.7% more than the S&P 500 on any given day. The stability factor score for Orchestra BioMed Holdings, Inc. is 28/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Orchestra BioMed Holdings, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Orchestra BioMed Holdings, Inc. reported revenue of $4M and earnings per share (EPS) of $-1.11. Net income for the quarter was $-74M. Gross margin was 94.2%. Operating income came in at $-75M.

In FY 2025, Orchestra BioMed Holdings, Inc. reported revenue of $33M and earnings per share (EPS) of $-1.11. Net income for the quarter was $-53M. Gross margin was 99.4%. Revenue grew 1169.2% year-over-year compared to FY 2024. Operating income came in at $-52M.

In Q3 2025, Orchestra BioMed Holdings, Inc. reported revenue of $861,000 and earnings per share (EPS) of $-0.40. Net income for the quarter was $-21M. Gross margin was 94.3%. Revenue grew -12.8% year-over-year compared to Q3 2024. Operating income came in at $-20M.

In Q2 2025, Orchestra BioMed Holdings, Inc. reported revenue of $836,000 and earnings per share (EPS) of $-0.50. Net income for the quarter was $-19M. Gross margin was 94.5%. Revenue grew 7.5% year-over-year compared to Q2 2024. Operating income came in at $-19M.

Over the past 8 quarters, Orchestra BioMed Holdings, Inc. has demonstrated a growth trajectory, with revenue expanding from $778,000 to $4M. Investors analyzing OBIO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

OBIO Dividend Yield and Income Analysis

Orchestra BioMed Holdings, Inc. (OBIO) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

OBIO Momentum and Technical Analysis Profile

Orchestra BioMed Holdings, Inc. (OBIO) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 29/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 20/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

OBIO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Orchestra BioMed Holdings, Inc. (OBIO) ranks #324 out of 838 stocks based on the Blank Capital composite score. This places OBIO in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing OBIO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OBIO vs S&P 500 (SPY) comparison to assess how Orchestra BioMed Holdings, Inc. stacks up against the broader market across all factor dimensions.

OBIO Next Earnings Date

No upcoming earnings date has been announced for Orchestra BioMed Holdings, Inc. (OBIO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy OBIO? — Investment Thesis Summary

The quantitative profile for Orchestra BioMed Holdings, Inc. suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 19/100 indicates premium valuation. High volatility (stability score 28/100) increases portfolio risk.

In summary, Orchestra BioMed Holdings, Inc. (OBIO) earns a Reduce rating with a composite score of 30.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OBIO stock.

Related Resources for OBIO Investors

Explore more research and tools: OBIO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OBIO head-to-head with peers: OBIO vs AZN, OBIO vs SLGL, OBIO vs VMD.